Boston Scientific

Baylis Medical Company is a supplier of high-technology cardiology, endovascular, and oncology products. The company's Radio Frequency Puncture System is a technology that creates controlled perforations in cardiac and vascular tissues. This ground breaking technology was designed for use by pediatric interventional cardiologists to treat pulmonary atresia. It is now the recognized worldwide gold standard for treating this disease. In addition to their development efforts, Baylis Medical has a long history of importing and distributing products into the Canadian market. The company represents numerous manufacturers of cardiology, pain management, and radiology products in Canada. Baylis Medical enjoys an excellent reputation with the medical community. This reputation has been built on their commitment to offering state-of-the-art products along with exceptional service to all their customers.

DeVoro Medical is a developer of a medical device intended to restore blood flow. The company was founded in 2018 by and is based in Fremont, California.

Nectero Medical develops a novel treatment to stabilize growth and prevent rupture of mid-sized abdominal aortic aneurysms. The company was founded in 2017 and is headquartered in Dover, Delaware, United States.

Append Medical develops a next-generation transcatheter Left Atrial Appendage (LAA) closure system. The Append Medical solution is in the pre-clinical in-vivo trial phase. It is intended to become a differentiated solution in the LAA closure market, which has been estimated to reach $25B within several years. This is the second-fastest growing segment of the medical device market, with potential sales of $500M in 2019. Append Medical is a member of MEDX Xelerator, a medtech incubator backed by Boston Scientific, Intellectual Ventures, MEDX Ventures and Sheba Medical Center.

The Lumenis surgical laser division is a global leader in advanced medical laser equipment and surgical laser technology. Lumenis is a pioneer in the field of laser for surgery and its cutting-edge devices are being used by top medical professionals and facilities around the world. The company Provides Urology laser, Gynecology laser, ENT laser and more systems for medical applications.

Preventice Solutions is a privately-held company that offers a portfolio of mobile cardiac health solutions and services. It is a developer of mobile health solutions and remote monitoring services, connecting patients, clinicians, and hospitals.

Farapulse commercialize an innovative collection of catheter-based tools used to treat atrial fibrillation. Farapulse are working to make atrial fibrillation ablation safer, faster, more accessible, and less expensive for millions of people.

Preventice Solutions is a privately-held company that offers a portfolio of mobile cardiac health solutions and services. It is a developer of mobile health solutions and remote monitoring services, connecting patients, clinicians, and hospitals.

SetPoint Medical is a privately held clinical-stage healthcare company dedicated to treating patients with chronic autoimmune diseases. The company is developing a novel platform designed to stimulate the vagus nerve to activate the inflammatory reflex to produce a systemic immune-restorative effect. SetPoint Medical’s platform technology is designed to offer patients and providers a treatment alternative for rheumatoid arthritis, inflammatory bowel disease and other chronic autoimmune conditions with potentially less risk and cost than drug therapy.

Saluda Medical is a commercial-stage medical device company that develops treatments for chronic neurological conditions using a novel closed-loop, dose-control neuromodulation platform. Its novel neuromodulation platform is designed to sense and measure neural responses to stimulation and automatically adjust therapy based on real-time neurophysiological feedback.

InterVene is a medical device company focused on innovating treatments for chronic venous disease, particularly deep vein valve failure. The company’s BlueLeaf™ Endovenous Valve Formation System offers a non-implantable solution to address severe venous conditions. InterVene aims to improve patient outcomes by providing minimally invasive therapies for venous stasis ulcers and related symptoms.

VertiFlex, Inc., a medical device company, provides minimally invasive and motion preserving spinal surgery technologies in the United States and internationally. The company offers superion interspinous spacer, a percutaneous titanium implant that fits between the spinous processes in the lumbar spine. Its Superion is a motion-preserving interspinous spacer for the treatment of moderate spinal stenosis. Vertiflex Inc was founded in 2005 and is headquartered in California, USA.

Pulmonx is the global leader in interventional procedures for the treatment of COPD. It develops and markets non-surgical technologies for the assessment and treatment of patients with severe emphysema, a progressive and life-threatening form of COPD. The Pulmonx solution, which is comprised of the Zephyr Endobronchial Valve (Zephyr Valve), the Chartis Pulmonary Assessment System (Chartis System) and the StratX Lung Analysis Platform, is designed to treat severe emphysema patients who, despite medical management, are still profoundly symptomatic and either do not want or are ineligible for surgical approaches. The technology is supported by a compelling body of clinical evidence including over 100 published scientific articles regarding the clinical benefits of Zephyr Valves. FDA granted the Zephyr Valve a ‘breakthrough device’ designation, and in June 2018 Pulmonx received FDA pre-market approval to commercialize our Zephyr Valve. The Zephyr Valve is now commercially available and physicians in more than 25 countries around the world routinely use the Zephyr Valves to improve the lives of patients with severe emphysema, with over 76,000 valves used to treat more than 19,000 patients worldwide to date.

BTG acquires, develops, manufactures, and commercializes pharmaceutical products in the United States, Europe, and internationally. It operates through three segments: Interventional Medicine, Pharmaceuticals, and Licensing. The Interventional Medicine segment offers interventional oncology products and systems, such as beads and TheraSphere for treatment of liver cancer; and GALIL medical system, a cryoablation technology for use in kidney cancer and other indications. This segment also provides interventional vascular products consisting of EKOS system, an ultrasonic catheter drug delivery device used in the treatment of blood clots; Varithena for the treatment of varicose veins; and PneumRx Coil for the treatment of emphysema, a debilitating lung disease. The Pharmaceuticals segment offers antidote products, such as CroFab for the treatment of crotalid snake envenomations; DigiFab for the treatment of digoxin toxicity; and Voraxaze for high-dose methotrexate toxicity. The Licensing segment provides Zytiga for treatment of prostate cancer; Two-Part Hip Cup; and Lemtrada. The company also manufactures and commercializes therapeutic ultrasound devices, and roxwood systems, as well as develops venous thrombus management devices. British Technology Group International that began operation in 1948 became BTG in March 1995. Its headquarters is in London in the United Kingdom.

SpaceOAR is a privately held medical device company developing in-situ formed, space-filling hydrogels specifically for radiation oncology and cancer surgery indications. Its hydrogel is clinically proven to minimize side effects and protect the quality of life for prostate cancer patients undergoing radiation therapy that enables healthcare providers to minimize urinary, sexual, and bowel side effects of the patients. It was founded in 2007 and is headquartered in Bedford, Massachusetts.

VENITI is the first medical device company developing a suite of innovative technology and solutions that will provide comprehensive treatment across the venous disease continuum. Venous disease refers to all conditions related to or caused by veins that become diseased or abnormal. This encompasses a broad set of maladies. The venous disease cycle begins when vein walls become weak or damaged, or the valves are stretched or injured, and can no longer prevent reflux (backward flow of blood). Once the veins lose their ability to convey blood without reflux, the progressive venous disease cycle has begun. This is commonly referred to as chronic venous insufficiency, or CVI. The blood will begin to back up into the peripheral veins, causing venous hypertension, potential thrombosis (clotting), and leading to even more damage of the vein walls and valves. This in turn leads to more reflux. The VENITI team of experts in science, technology and business are currently developing the VENITI VICI VENOUS STENT® System. Through this, and other, innovative technology, VENITI will achieve results that sets it apart in addressing the challenges specific to the venous system and venous disease.

Claret Medical, Inc. develops a series of cerebral vascular protection systems for transcatheter aortic valve implantation, surgical, and other interventional procedures. The company’s products include Claret Medical Montage, a dual filter system and percutaneously delivered embolic protection device to capture and remove debris disloged during vascular procedures; and small (6F) catheters that are inserted into the patient's right arm to protect the patient’s brain during interventional procedures where embolic debris might be released. It offers its products for use as an embolic protection system to capture and remove embolic material (thrombus/debris) that may enter the cerebral vascular system during endovascular procedures. The company was incorporated in 2009 and is based in Santa Rosa, California.

Cryterion Medical has developing a single-shot cryoablation platform for the treatment of atrial fibrillation (AF). Cryterion is headquartered in Carlsbad, California, with offices in Montreal, Canada and Wexford, Ireland. The Cryterion Medical cryoablation platform uses cryothermal energy to interrupt the irregular electrical signals that can cause AF. Developed with a next-generation balloon catheter, advanced mapping catheter, steerable sheath and enhanced console, the system is designed to streamline overall procedural workflow, enhance maneuverability and improve positioning in challenging anatomy.

RenovoRx is a developing innovative solutions for targeted delivery of fluids, including diagnostic and therapeutic agents, to selected sites in the peripheral vascular system. RenovoRx received FDA clearance for the RenovoCath™ RC120 and is currently introducing this innovative technology to the clinical market. RenovoRx has a motivated Management Team with broad experience and an exciting vision for the future of targeted delivery. The company also has a broad Advisory Board of interventional radiologists, surgical oncologists and gastroenterologists that guide the company's clinical development strategies. RenovoRx is backed by a strong Board of Directors committed to long-term, continuous support of the company, whose members provide critical expertise in the medical and biotechnology industry and the visionary thinking to succeed.

NVISION MEDICAL Corporation operates in the healthcare sector. The company was incorporated in 2009 and is based in Saratoga, California. nVision is a privately-held medical device company dedicated to filling the void in women’s health innovation. Since its founding in 2011, the company has relentlessly focused on developing devices to enable clinicians to assess the health of previously inaccessible parts of the female reproductive tract.

Securus Medical Group engages in the development of clinical tools to improve the safety and efficacy of ablation therapy by providing real-time, non-contact, high-resolution tissue temperature monitoring, and mapping products. The company engages in developing real-time, noncontact, thermal mapping systems to determine intrabody tissue temperatures.

NxThera develops medical technologies to treat a variety of endourology conditions, including BPH. The company's technology platform utilizes a simple, minimally invasive, vapor therapy designed to measurably improve urinary flow and patient quality of life. BPH afflicts more than 32 million men in the United States.

EMcision is a medical device company committed to improving the lives of cancer patients. It provides Habib EndoHPB, an endoscopic bipolar RF probe developed to ablate tissue in the gastro-intestinal tract; Habib Endoblate, a bipolar RF probe that is particularly effective for performing endoluminal ablation of gastrointestinal tumours that are not suitable for surgical resection; Habib VesCoag, an endovascular RF catheter that is particularly effective for precise vascular occlusion.

Millipede develops a catheter-based solution to treat mitral and tricuspid regurgitation, restoring health and expanding options for physicians, and global patients.

Millipede develops a catheter-based solution to treat mitral and tricuspid regurgitation, restoring health and expanding options for physicians, and global patients.

Apama Medical is a privately-held medical device company focused on the rapidly growing electrophysiology (EP) market.

SetPoint Medical is a privately held clinical-stage healthcare company dedicated to treating patients with chronic autoimmune diseases. The company is developing a novel platform designed to stimulate the vagus nerve to activate the inflammatory reflex to produce a systemic immune-restorative effect. SetPoint Medical’s platform technology is designed to offer patients and providers a treatment alternative for rheumatoid arthritis, inflammatory bowel disease and other chronic autoimmune conditions with potentially less risk and cost than drug therapy.

Channel Medsystems is a medical device company offering cryotherapy devices for endometrial cryoablation. Its mission is to empower every woman to take control of her health journey and live their best life.

Neuros Medical is a neuromodulation company, is focused on developing proprietary therapies for the unmet needs of patients worldwide. The Company's patented platform technology, Electrical Nerve Block, is focused on the elimination of chronic pain in a variety of applications including neuroma/residual limb pain, chronic post-surgical pain, and chronic migraine.

Amphora Medical is a Minnesota-based developer of medical devices and instruments. The company is currently working on a novel cystoscopic device that has the potential to improve bladder function and quality of life for people with Overactive Bladder Syndrome (OAB). It was founded in 2011 and is headquartered in Minneapolis, Minnesota, United States.

NeuroTronik, spun out of medical technology incubator Synecor, is developing a medical device that could take the place of drugs currently used to heart failure. Read more about the company's technology,

Symetis is a Swiss Company developing innovative minimally invasive heart valve replacement therapies for patients suffering from heart valve diseases. Symetis is dedicated to improving patient care and safety by offering simple, accurate solutions for heart valve replacement. Its proprietary Acurateâ„¢Aortic Valve Replacement System features a unique self-positioning design providing facile implant positioning and alignment as well as unrivalled ease of use.

Pulmonx is the global leader in interventional procedures for the treatment of COPD. It develops and markets non-surgical technologies for the assessment and treatment of patients with severe emphysema, a progressive and life-threatening form of COPD. The Pulmonx solution, which is comprised of the Zephyr Endobronchial Valve (Zephyr Valve), the Chartis Pulmonary Assessment System (Chartis System) and the StratX Lung Analysis Platform, is designed to treat severe emphysema patients who, despite medical management, are still profoundly symptomatic and either do not want or are ineligible for surgical approaches. The technology is supported by a compelling body of clinical evidence including over 100 published scientific articles regarding the clinical benefits of Zephyr Valves. FDA granted the Zephyr Valve a ‘breakthrough device’ designation, and in June 2018 Pulmonx received FDA pre-market approval to commercialize our Zephyr Valve. The Zephyr Valve is now commercially available and physicians in more than 25 countries around the world routinely use the Zephyr Valves to improve the lives of patients with severe emphysema, with over 76,000 valves used to treat more than 19,000 patients worldwide to date.

Neovasc Inc. is a specialty medical device company that develops and manufactures products for the rapidly growing cardiovascular device marketplace.Neovasc Inc. offers pericardial tissue processing, vascular product development, design, and manufacturing solutions to industry partners.

The LumenR Tissue Retractor System is currently in development for use during endoscopic resection of lesions in the colon, esophagus or stomach.

EndoChoice is a medtech company focused on the manufacturing and commercialization of platform technologies including devices, diagnostics, infection control and endoscopic imaging for specialists treating a wide range of gastrointestinal (GI) diseases. EndoChoice leverages its direct sales organization to serve more than 2,000 customers in the United States and works with 34 distribution partners world-wide. The Company was founded in 2008 and has rapidly developed a proprietary product portfolio, which includes the revolutionary Full Spectrum Endoscopy™ System (Fuse™). The Fuse System is comprised of colonoscopes and gastroscopes with multiple imagers so doctors can see more of the GI tract for diagnosis and treatment. The Fuse colonoscope provides a field of view of 330 degrees versus 170 degrees from traditional endoscopes. In clinical studies, Fuse found 70% more polyps than traditional colonoscopies. 2013 marked the fourth consecutive year EndoChoice was recognized as one of the fastest growing companies in the U.S. by Inc. Magazine. To learn more, visit www.endochoice.com

Securus Medical Group engages in the development of clinical tools to improve the safety and efficacy of ablation therapy by providing real-time, non-contact, high-resolution tissue temperature monitoring, and mapping products. The company engages in developing real-time, noncontact, thermal mapping systems to determine intrabody tissue temperatures.

Cosman Medical offers a comprehensive range of radiofrequency (RF) generators, electrodes, and cannulae for neurosurgery and pain management in interventional anesthesiology and podiatry. Radiofrequency (RF) nerve ablation is a versatile medical technology with a 60-year track record in medicine. It can be used to treat chronic back and neck pain, including pain from facet joint dysfunction, lumbago, sciatica, nerve impingement, intervertebral disc dysfunction, sacroiliac joint dysfunction, headaches, postoperative pain, complex regional pain syndrome (CRPS), reflex sympathetic dystrophy (RSD). It can also be used to treat severe, intractable pain such as that arising from end-stage cancer (cordotomy), nerve root avulsion injury (DREZ and DREZ nucleus caudalis), and trigeminal neuralgia (PSR). In podiatry, RF is used to treat intractable pain from foot, heel, and ankle disorders like plantar fasciitis and Morton's Neuroma. In functional neurosurgery, RF can be used to treat movement disorders such as Parkinson's Disease, essential tremor, and spasticity.

NxThera develops medical technologies to treat a variety of endourology conditions, including BPH. The company's technology platform utilizes a simple, minimally invasive, vapor therapy designed to measurably improve urinary flow and patient quality of life. BPH afflicts more than 32 million men in the United States.

TVA Medical, Inc. (TVA) is a medical device company developing innovative, minimally invasive therapies for treatment of End-Stage Renal Disease (ESRD). The company is funded by Santé Ventures.

Channel Medsystems is a medical device company offering cryotherapy devices for endometrial cryoablation. Its mission is to empower every woman to take control of her health journey and live their best life.

SetPoint Medical is a privately held clinical-stage healthcare company dedicated to treating patients with chronic autoimmune diseases. The company is developing a novel platform designed to stimulate the vagus nerve to activate the inflammatory reflex to produce a systemic immune-restorative effect. SetPoint Medical’s platform technology is designed to offer patients and providers a treatment alternative for rheumatoid arthritis, inflammatory bowel disease and other chronic autoimmune conditions with potentially less risk and cost than drug therapy.

Preventice Solutions is a privately-held company that offers a portfolio of mobile cardiac health solutions and services. It is a developer of mobile health solutions and remote monitoring services, connecting patients, clinicians, and hospitals.

American Medical Systems, a wholly owned subsidiary of Endo Pharmaceutical headquartered in Minnetonka, Minn., is a diversified supplier of medical devices and procedures to cure incontinence, erectile dysfunction, benign prostatic hyperplasia (BPH), pelvic floor prolapse and other pelvic disorders in men and women. These disorders can significantly diminish oneâ€:tm:s quality of life and profoundly affect social relationships. In recent years, the number of people seeking treatment has increased markedly as a result of longer lives, higher quality-of-life expectations and greater awareness of new treatment alternatives. American Medical Systemsâ€:tm: products reduce or eliminate the incapacitating effects of these diseases, often through minimally invasive therapies. The companyâ€:tm:s products were used to treat more than 340,000 patients in 2010.

Xlumena develops image-guided therapeutic endoscopy products. It develops Bile Duct Stenting, a self-expanding anchor stent and precision XL delivery system. The company also develops Pseudocyst Drainage, an integrated XF system designed to enable reliable pseudocyst drainage; and Hiatal Hernia Repair that enables the repair of a hiatal hernia from inside the GI lumen. Xlumena was founded in 2007 and is based in Mountain View, California.

InterVene is a medical device company focused on innovating treatments for chronic venous disease, particularly deep vein valve failure. The company’s BlueLeaf™ Endovenous Valve Formation System offers a non-implantable solution to address severe venous conditions. InterVene aims to improve patient outcomes by providing minimally invasive therapies for venous stasis ulcers and related symptoms.

Iogyn, Inc. is a medical device start-up company located in Cupertino, California. The Company has developed the Symphion System, designed for endoscopically-controlled Radiofrequency bi-polar resection and removal of soft tissue, such as polyps, myomas and prostate adenomas, requiring endoscopic visualization under continuous flow conditions.

StarMedTec is an internationally established manufacturer of medical laser systems. With its laser surgery solutions, it covers the medical disciplines of urology, gynecology, gastroenterology, ENT, pneumology, and general surgery.

Sensible Medical Innovation Ltd. is introducing a breakthrough sensing and monitoring technology providing actionable and accurate data for guiding the management and treatment of several chronic medical conditions representing today’s biggest burden on US and worldwide healthcare budgets.

SetPoint Medical is a privately held clinical-stage healthcare company dedicated to treating patients with chronic autoimmune diseases. The company is developing a novel platform designed to stimulate the vagus nerve to activate the inflammatory reflex to produce a systemic immune-restorative effect. SetPoint Medical’s platform technology is designed to offer patients and providers a treatment alternative for rheumatoid arthritis, inflammatory bowel disease and other chronic autoimmune conditions with potentially less risk and cost than drug therapy.

BaroSense is committed to develop and commercialize novel anti-obesity products that provide a meaningful contribution to this leading healthcare problem facing the United States today. BaroSense was conceived in order to create a safe, simple, effective, and minimally invasive alternative to the surgical treatment of obesity - an innovative approach to assist those people who need help beyond traditional diets, and who wish to avoid extensive, irreversible surgery.

For over 100 years, C. R. Bard, Inc. has been Advancing the Delivery of Healthcare® by creating innovative products and services that meet the needs of healthcare providers and patients. Today, Bard is a leader in products that focus on Disease State Management in three areas: Vascular, Urology, and Oncology. To complement these areas, Bard has a complete line of advanced Surgical Specialty Products and Services. A division of C. R. Bard Inc., Bard Electrophysiology is a global company focused on the development and delivery of a broad range of devices for the diagnosis and treatment of cardiac arrhythmias. Bard Electrophysiology offers a full product portfolio which includes advanced RF ablation and mapping catheters, diagnostic catheters, computer-based electrophysiology mapping and recording systems, temporary pacing electrodes, and vascular/cardiac access devices. Through our rich history of commitment to innovative products, unparalleled support, and a dedication to education worldwide, Bard Electrophysiology continues to be a leader in the field of EP.

Channel Medsystems is a medical device company offering cryotherapy devices for endometrial cryoablation. Its mission is to empower every woman to take control of her health journey and live their best life.

BAROnova, founded in 2006 and based in Goleta, CA, is a clinical-stage medical-device company focused on developing non-surgical non-pharmacologic devices to induce weight loss.

Vessix Vascular, Inc. (formerly known as Minnow Medical, Inc.). Vessix is a privately-held pre-revenue stage company developing novel radiofrequency balloon catheter technology. The Company's initial product, the ZCath® System, has a CE Mark for use in reducing plaque in peripheral leg arteries.

Rhythmia Medical, Inc., an early stage medical device company, develops medical devices for the treatment of cardiac arrhythmia. It focuses on developing a 3D mapping system to enable an improvement in the catheter ablation procedures used to treat tachy-arrhythmias, such as atrial fibrillation.

BridgePoint Medical, a private company with headquarters in Minneapolis, Minnesota, is focused on developing innovative and proprietary technology in the field of interventional cardiology for access to and treatment of chronic total occlusions.

Neuros Medical is a neuromodulation company, is focused on developing proprietary therapies for the unmet needs of patients worldwide. The Company's patented platform technology, Electrical Nerve Block, is focused on the elimination of chronic pain in a variety of applications including neuroma/residual limb pain, chronic post-surgical pain, and chronic migraine.

Cameron Health, Inc., a development stage medical device company, is creating the next generation of implantable electronic device utilizing state-of-the-art technologies. They are a team of specialized, high technology, creative individuals with decades of experience in solving difficult medical problems. Their current target is the development of a family of devices that will afford patient treatment that has been, until now, unattainable with the current therapeutic modalities and technologies.

Revascular Therapeutics is a medical device company that develops solutions for the intravascular treatment of complex lesions and total occlusions. Revascular develops percutaneous medical devices to reopen occluded vessels.

Atritech is a private company located in Minneapolis, Minnesota. The company was founded in 2000 and has developed proprietary technology focused on replacing long term anticoagulation therapy for patients with non-valvular atrial fibrillation at risk of stroke. The first implants of the WATCHMAN® Left Atrial Appendage Closure Technology were performed in Germany in August of 2002 and in the United States in October of 2003. Since then the company has conducted a large randomized clinical trial comparing the WATCHMAN® Left Atrial Appendage Closure Technology to long term Warfarin therapy in patients with non-valvular atrial fibrillation at risk of stroke. The WATCHMAN® Device is CE Marked and available in many markets outside the United States. The WATCHMAN® Device is currently available For Investigational Use Only in the United States.

IntElect Medical, Inc., an early stage medical device company, develops and commercializes deep brain stimulation (DBS) therapies and technology for patients suffering with disabilities from stroke and traumatic brain injury. The company focuses on developing an implantable neuromodulation system for stroke and traumatic brain injury recovery.

Sadra Medical is exploring new minimally invasive alternatives to traditional surgical valve replacement. The company hopes that devices allowing such procedural advances will facilitate and enhance treatment of aortic valve disease. Sadra Medical is dedicated to developing innovative new therapies for the treatment of aortic valve disease. By developing minimally invasive alternatives to traditional surgical valve replacement, the company seeks to help improve patient care and make valve replacement possible for broader range of patients. Treatment of aortic valve disease remains a significant and growing unmet clinical need. As many as 3 million people in U.S. have aortic valve stenosis; however, only a small percentage of those are treated with the current standard of care, valve replacement during open-heart surgery using cardiopulmonary bypass. By developing a highly effective aortic valve replacement that is designed to reduce the risks and morbidity associated with open surgical valve replacement, Sadra Medical seeks to provide a therapeutic option for patients who are not being treated today. Sadra Medical, a subsidiary of Boston Scientific.

Asthmatx, Inc., a medical device company, focuses on developing and commercializing a therapeutic treatment for asthma in the United States. The company has developed a technology that is designed to deliver controlled thermal energy to the airways of adult patients to reduce the mass of airway smooth muscle in a procedure called Bronchial Thermoplasty. Asthmatx offers an interventional medical device, called the Alair System, for the bronchoscopic treatment of patients with moderate to severe asthma. Asthmatx was founded in 2003 and is headquartered in Mountain View, California. As of October 26, 2010, Asthmatx operates as a wholly-owned subsidiary of [Boston Scientific](/organization/boston-scientific).

Sadra Medical is exploring new minimally invasive alternatives to traditional surgical valve replacement. The company hopes that devices allowing such procedural advances will facilitate and enhance treatment of aortic valve disease. Sadra Medical is dedicated to developing innovative new therapies for the treatment of aortic valve disease. By developing minimally invasive alternatives to traditional surgical valve replacement, the company seeks to help improve patient care and make valve replacement possible for broader range of patients. Treatment of aortic valve disease remains a significant and growing unmet clinical need. As many as 3 million people in U.S. have aortic valve stenosis; however, only a small percentage of those are treated with the current standard of care, valve replacement during open-heart surgery using cardiopulmonary bypass. By developing a highly effective aortic valve replacement that is designed to reduce the risks and morbidity associated with open surgical valve replacement, Sadra Medical seeks to provide a therapeutic option for patients who are not being treated today. Sadra Medical, a subsidiary of Boston Scientific.

IntElect Medical, Inc., an early stage medical device company, develops and commercializes deep brain stimulation (DBS) therapies and technology for patients suffering with disabilities from stroke and traumatic brain injury. The company focuses on developing an implantable neuromodulation system for stroke and traumatic brain injury recovery.

Cameron Health, Inc., a development stage medical device company, is creating the next generation of implantable electronic device utilizing state-of-the-art technologies. They are a team of specialized, high technology, creative individuals with decades of experience in solving difficult medical problems. Their current target is the development of a family of devices that will afford patient treatment that has been, until now, unattainable with the current therapeutic modalities and technologies.

CryoCor, Inc. is a medical technology company headquartered in San Diego, California developing products that use cryogenic technology to treat cardiac rhythm disorders called arrhythmias. Cardiac cryoablation is a non-surgical, minimally-invasive procedure in which a cardiologist inserts a catheter into a blood vessel in the leg of an afflicted individual and advances it into the heart. Once it reaches the targeted cardiac tissue, the catheter tip temperature is lowered to approximately -90°C — thereby blocking the conduction of the abnormal signals causing the heart to beat inappropriately and restoring its function to normal. The CryoCor™ Cardiac Cryoablation System consists of a cryoablation catheter that is connected to an articulating arm mounted on the company’s refrigeration console. To facilitate catheter placement, the System can be used in conjunction with CryoCor introducer sheaths. The System has been approved for use in Europe and has been commercially available there since 2002. CryoCor's European activities are managed by its wholly-owned subsidiary in Cologne, Germany which directs the company's marketing, sales and post-market clinical activities. The CryoCor Cardiac Cryoablation System is currently in use at multiple medical centers throughout Europe.

Remon Medical Technologies is a development-stage company focused on communication technology for medical device applications. It offers RemonCHF, a device that monitors the hemodynamic status of patients with congestive heart failure; and RemonAAA, a device that monitors pressure following an endograft procedure in AAA patients. The company is based in Caesarea, Israel.

IntElect Medical, Inc., an early stage medical device company, develops and commercializes deep brain stimulation (DBS) therapies and technology for patients suffering with disabilities from stroke and traumatic brain injury. The company focuses on developing an implantable neuromodulation system for stroke and traumatic brain injury recovery.

ORQIS Medical Corporation operates as a medical device company. It develops and sells minimally invasive devices for improving cardiac performance through aortic flow therapy. It offers Cancion System, a heart failure treatment that uses continuous aortic flow augmentation technology to improve symptoms of heart failure and change the underlying course of the disease for patients hospitalized for de-compensated heart failure. The company’s products also include Exeleras System to treat chronic heart failure patients.

EndoTex Interventional Systems, Inc., a development stage medical device company, engages in the development and manufacture of less-invasive medical devices for use in the vascular system. It provides solutions for treating carotid artery disease. The company was founded in 1995 and is based in Cupertino, California. As of January 4, 2007, EndoTex Interventional Systems, Inc. is a subsidiary of Boston Scientific Corp.

Health Hero Network, Inc. develops and markets technology solutions for remote health monitoring and management. The company provides health management programs delivering personalized daily monitoring and patient education, and information to care providers. It also offers Health Buddy system that serves as the interface between patients at home and care providers, facilitating patient education and monitoring of chronic conditions. The company's Health Buddy system includes monitoring technologies, clinical information databases, Internet-enabled decision support tools, health management programs, and content development software tools. It serves hospitals, health plans, government health organizations, disease management companies, and pharmaceutical companies or universities conducting clinical trials or studies. The company was founded in 1988 and is based in Palo Alto, California. As of December 19, 2007, Health Hero Network, Inc. operates as a subsidiary of Robert Bosch GMBH.

Sadra Medical is exploring new minimally invasive alternatives to traditional surgical valve replacement. The company hopes that devices allowing such procedural advances will facilitate and enhance treatment of aortic valve disease. Sadra Medical is dedicated to developing innovative new therapies for the treatment of aortic valve disease. By developing minimally invasive alternatives to traditional surgical valve replacement, the company seeks to help improve patient care and make valve replacement possible for broader range of patients. Treatment of aortic valve disease remains a significant and growing unmet clinical need. As many as 3 million people in U.S. have aortic valve stenosis; however, only a small percentage of those are treated with the current standard of care, valve replacement during open-heart surgery using cardiopulmonary bypass. By developing a highly effective aortic valve replacement that is designed to reduce the risks and morbidity associated with open surgical valve replacement, Sadra Medical seeks to provide a therapeutic option for patients who are not being treated today. Sadra Medical, a subsidiary of Boston Scientific.

Solace Therapeutics is a medical device company that develops and commercializes non-surgical office-based treatments for common bladder disorders, such as stress urinary incontinence (SUI), overactive bladder (OAB), male voiding dysfunction and lower urinary tract symptoms (LUTS). It is dedicated to improving the patient’s quality of life by eliminating side effects typically associated with current drug and surgical therapies. The company offers a technology that is designed to offer patients an office-based therapy that does not require anesthesia or surgery, no lifestyle change required, before or after treatment, and reversible at any time.

Cameron Health, Inc., a development stage medical device company, is creating the next generation of implantable electronic device utilizing state-of-the-art technologies. They are a team of specialized, high technology, creative individuals with decades of experience in solving difficult medical problems. Their current target is the development of a family of devices that will afford patient treatment that has been, until now, unattainable with the current therapeutic modalities and technologies.

Guidant Corporation is engaged in the design and manufacture of cardiovascular medical products. It is operating as a part off Boston Scientific and Abbott Labs, manufacturing artificial cardiac pacemakers,implantable cardioverter-defibrillators, stents, and more. Its medical devices help patients with heart diseases in returning to active and productive lives and physicians for improving patient management and clinical outcomes. Guidant Corporation is headquartered in Indianapolis, Indiana and was founded in 1994.

Cameron Health, Inc., a development stage medical device company, is creating the next generation of implantable electronic device utilizing state-of-the-art technologies. They are a team of specialized, high technology, creative individuals with decades of experience in solving difficult medical problems. Their current target is the development of a family of devices that will afford patient treatment that has been, until now, unattainable with the current therapeutic modalities and technologies.

Adiana, Inc. engages in the development and testing of transcervical sterilization system for permanent birth control. It develops Complete TCS, which consists of a radiofrequency generator, delivery catheter, and implantable matrix. The company was founded in 1997 and is based in Redwood City, California. As of March 16, 2007, Adiana, Inc. is a subsidiary of CYTYC Corp.

BrainsGate's platform technology involves electrical stimulation of the Spheno-Palatine Ganglion (SPG), a nervous center known to increase cerebral blood flow. BrainsGate is exploring several applications for its technology, and is currently focusing on treatment of acute ischemic stroke. Building on its technology, the Company has developed the ISS, based on a miniature electrode implanted at the roof of the mouth in a bed side, minimally invasive, local anesthesia procedure comparable to dental treatment. In 2008, the company completed ImPACT-1, a pilot clinical trial for acute ischemic stroke with promising results. In 2011 the Company completed a 300 patients RCT pivotal trial that further substantiated the safety and efficacy of its treatment for acute ischemic stroke patients. BrainsGate is currently running the ImpACT-24b, a multi-national, randomized, double-blind, sham-controlled pivotal study to assess the safety and efficacy of its treatment for stroke patients in a 24-hour window.

3F Therapeutics develops, manufactures, and markets cardiovascular devices. It offers invasive and transapical aortic heart replacement technology, including enabling aortic heart valve, entrata aortic valve system, and endurance valve system to reduce surgical cross-clamp and cardio-pulmonary bypass time, utilization for congestive heart failure.

Advanced Stent Technologies designs and develops stents and stent delivery systems for the treatment of atherosclerosis at bifurcations in the coronary vasculature. The company’s flagship product, the SLK-View stent and delivery system, is used for treating diseased bifurcations by providing stability to the main artery while maintaining access to the side branch vessel. Advanced Stent Technologies was founded in 1997 and is based in Pleasanton, California.

VisionCare Ophthalmic Technologies, Inc., a Saratoga, CA-based developer of advanced visual prosthetic devices designed to improve vision in patients with end-stage age-related macular degeneration (AMD). VisionCare Ophthalmic Technologies (VisionCare) is a privately held specialty medical device company engaged in the research, development, manufacture, and marketing of proprietary implantable ophthalmic devices and technologies that are intended to significantly improve vision and quality of life for individuals with untreatable retinal disorders. Our lead product, the Implantable Miniature Telescope (by Dr. Isaac Lipshitz), is the first FDA-approved implantable medical device demonstrated to improve vision and quality of life in individuals with the most advanced, irreversible form of age-related macular degeneration (AMD) – End-Stage AMD. End-Stage AMD is the leading cause of blindness in older Americans. The telescope implant is integral to the CentraSight™ treatment program which has been developed to help patients follow the necessary steps for proper diagnosis, surgical evaluation, and postoperative care. Our goal is to help patients reconnect to the things in life they love to see and do. To help achieve this, we will establish a high level of collaboration with our healthcare provider customers through a broad range of direct support programs and services.

REVA Medical develops bio resorbable polymers for vascular applications, to restore patient health for life through the application of biomaterials in the development and sale of implantable medical devices.

3F Therapeutics develops, manufactures, and markets cardiovascular devices. It offers invasive and transapical aortic heart replacement technology, including enabling aortic heart valve, entrata aortic valve system, and endurance valve system to reduce surgical cross-clamp and cardio-pulmonary bypass time, utilization for congestive heart failure.

Advanced Bionics Corporation develops implantable neurostimulation devices. The company develops and manufactures cochlear implants. Its devices restore hearing in the deaf and alleviate chronic pain. Advanced Bionics Corporation was founded in 1993 and is headquartered in Valencia, California with additional offices in Rixheim, France; Valencia, California; and Tokyo, Japan.

Broncus Technologies is a medical technology company focused on developing minimally-invasive medical devices for emphysema and other lung diseases. Broncus is investigating the Exhale emphysema product line to perform our patented treatment method called Airway Bypass. Airway Bypass could be the first minimally-invasive procedure for the treatment of homogeneous, or diffuse, emphysema, which constitutes the majority of the emphysema patient population. Broncus is currently enrolling patients worldwide in our pivotal EASE Trial investigating a treatment of severe homogeneous emphysema. Broncus is located in Mountain View, CA (San Francisco Bay area). Broncus International is located in Nyon, Switzerland.

Proxima Therapeutics develops radiation delivery systems for the treatment of solid cancerous tumors, with an initial focus on brain and breast cancer. Founded in 1996, the company’s marketed products include GliaSite RTS for brain cancer and MammoSite RTS for breast cancer. Proxima Therapeutics was acquired by Cytec Industries Inc. in 2005.

Enteric Medical Technologies designs, manufactures, and markets minimally invasive technologies for the treatment of gastroesophageal reflux disease. It offers Enteryx implantable biopolymer, which is injected into the wall of the esophagus to reinforce the LES. The company was incorporated in 1998 and is based in Foster City, California. As of June 12, 2002, Enteric Medical Technologies, Inc. operates as a subsidiary of Boston Scientific Corporation.

BioSurface Engineering Technologies, Inc., also known as BioSET, engages in developing proprietary therapeutic peptides as medical devices to improve bone and soft tissue repair. The company focuses on developing devices for orthobiologics applications. Its products include AMPLEX, an implantable combination device of the B2A peptide and a synthetic ceramic scaffold for use as a surgical bone graft implant for lumbar degenerative disc disease, as well as for use in spine, cervical spine, and foot and ankle fusion surgeries. The company also develops products for sports medicine applications based on its F2A peptide; and peptide signaling molecules and various scaffold biomaterials for use in musculoskeletal applications, including trauma, fracture repair, and other soft tissue treatments. BioSurface Engineering Technologies, Inc. was founded in 2001 and is based in Rockville, Maryland.

EndoTex Interventional Systems, Inc., a development stage medical device company, engages in the development and manufacture of less-invasive medical devices for use in the vascular system. It provides solutions for treating carotid artery disease. The company was founded in 1995 and is based in Cupertino, California. As of January 4, 2007, EndoTex Interventional Systems, Inc. is a subsidiary of Boston Scientific Corp.

Cardiac Pathways Corp manufactures minimally-invasive systems used by electrophysiologists to diagnose and treat cardiac tachyarrhythmia (abnormally rapid heart rhythms), which if untreated can cause palpitations, fainting, and sudden cardiac arrest. Cardiac Pathways' products consist principally of systems for performing ablation treatment (a nonsurgical, minimally-invasive technique for neutralizing heart tissue responsible for starting or maintaining a tachyarrhythmia) and for diagnostic mapping (locating the source of the tachyarrhythmia within the heart). Cardiac Pathways was issued a U.S. patent related to its Real-time Position Management Tracking System. Founded in 1991, Cardiac Pathways is based in Sunnyvale, California. As of August 6, 2001, it was acquired by Boston Scientific Corporation.

Catheter Innovations is a medical device company.

Embolic Protection manufactures devices for the prevention of embolic complications including stroke and heart attack during interventional vascular procedures.

Target Therapeutics develops and markets disposable medical devices that are used in minimally-invasive procedures for the treatment of vascular diseases. Target Therapeutics is based in Fremont, California, United States and operates as a subsidiary of Boston Scientific Corporation.

EP Technologies provides electrophysiology catheters and systems for use in minimally invasive procedures to diagnose and treat cardiac tachyarrhythmias. The company is based in Sunnyvale, California.

Boston Scientific Scimed, Inc. develops, manufactures, and markets medical devices used principally to treat cardiovascular disease.